Drug Discovery · Boston, MA · Founded 2022 · Privately Held (backing)
Developer of a generative biology medicine technology intended to accelerate new possibilities in drug discovery and development. Superluminal Medicines is based in Boston, MA and was founded in 2022. It was valued at $576 million at its Series B in Sep 2026, the last priced event on record. It has raised $158 million across 4 recorded rounds; the latest was a $65.5 million Series B in Sep 2026.
PMV mark · valuation
$576.3M
Oct 2026
Priced at
its Series B
Sep 2026
Total raised
$157.7M
Last round
Series B
Sep 2026
Cap table — not yet on record
Superluminal Medicines's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Superluminal Medicines with a free account
·The post-money valuation on its round
·The complete investor list: 12 names
·Watch Superluminal Medicines: the Monday email on marks, rounds and moves
Where does Superluminal Medicines's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Superluminal Medicines's 4 recorded funding rounds.
